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ABSTRACT 
 Staphylococcus aureus is an opportunistic pathogen responsible for significant morbidity 
and mortality in clinical settings in both humans and animals. This emerging pathogen is among 
the top three nosocomial pathogens in human and veterinary hospitals due to its ability to survive 
in these environments for long periods. This survival is likely the result of S. aureus’s production 
of biofilm: a protective matrix of bacterially secreted proteins that allow colonies to attach to 
environmental surfaces. Preventing and controlling this pathogen, specifically within small 
animal veterinary hospitals, becomes critical for two reasons. One, the presence of this pathogen 
increases the risk of animals developing a hospital-acquired infection. Two, this pathogen poses 
an occupational risk to veterinary hospital staff. Therefore, it is important to know the biofilm 
production potential and characteristics of S. aureus isolates in these animal facilities. This 
information can be used to more effectively prevent or control a uniquely natured biofilm-
producing S. aureus. To quantify biofilm production potential of S. aureus isolates the Crystal 
Violet (CV) assay is commonly used. This assay is preferred due to its simplicity, reliability, and 
quick throughput. With this assay isolates can be categorized as high, moderate, or non-biofilm 
producers. To adapt this assay, we used two high producer bacterial control strains NE95 and 
NE1241, a moderate producer wild type JE2 (WT), and a low producer NE1193 to validate the 
CV assay.  Assay optimization included changes in the quantity of overday culture growth, 
overnight incubation time, aspiration quantities, washing technique, and microplate reader 
absorbance wavelength. Through assay optimization a sensitive and specific CV assay was 
developed for the quantification and characterization of S. aureus biofilm production.  
 
INTRODUCTION 
 Staphylococcus aureus is an opportunistic pathogen responsible for significant health 
problems in humans1 and animals2. In addition to morbidity and mortality, it causes increased 
treatment fees, prolonged hospitalization, frustration, and grief. Rising reports of S. aureus 
infections make this pathogen now among the top nosocomial pathogens in human hospitals.3 
This rise in reports is particularly concerning due to its bidirectional transmissibility between 
humans and animals in household, community, and healthcare settings.4 Further heightening this 
concern are reports of S. aureus’s prevalence in veterinary hospitals. In one study of a veterinary 
hospital, S. aureus was reported to contaminate one in every five, or 18-20%, of contact 
surfaces.3 Van Balen et al.3 also reported that S. aureus can survive on inanimate objects and 
contact surfaces of veterinary origin for up to seven months. In a veterinary environment, S. 
aureus isolates have also been shown to circulate between multiple surfaces and areas within a 
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hospital for up to nine months. This prolonged environmental contamination exposes both 
animal patients and hospital staff, further increasing both staff risk of occupational related 
colonization and patient risk of hospital-acquired infection.3 Therefore, S. aureus is becoming a 
serious animal and public health concern. 
 In human medicine, S. aureus’s survival in the environment is at least in part due to its 
production of biofilm. In general, biofilms are surface-associated microbial communities 
encapsulated by a protective matrix of bacterially secreted carbohydrates, proteins, and DNA. In 
vivo, microbial cells within a biofilm are protected from the host immune system and acquire an 
enhanced resistance to antibiotics.5 In fact, it is reported that once a biofilm reaches its climax 
community, normal antimicrobial treatment concentrations become ineffective at eradication.6 
Biofilms can increase S. aureus’s antibiotic resistance up to 1,000 fold.7 In clinical 
environments, complex microbial communities within biofilm have enhanced cell-to-cell 
communications, allowing for rapid adaption to changing environments. For these reasons, in 
human healthcare settings, biofilms are therefore considered to be an important virulence factor 
of S. aureus8 and can complicate the control and eradication of S. aureus.7  
 To begin to understand how to control these biofilm-producing pathogens in hospital 
settings, it is first necessary to develop a complete understanding of biofilm formation. Briefly, 
in order for a microorganism to form biofilm a bacterially secreted matrix and adherable surface 
must be present. Development of a biofilm involves two phases, attachment and maturation, 
which lead to a complex switch in growth mode, from planktonic (floating) to sessile (attached).7 
Initially, attachment to a surface is promoted by specific bacterial adhesions called microbial 
surface components recognizing adhesive matrix molecules (MSCRAMMS). Once attached, the 
maturation phase follows and bacteria accumulate as they adhere to each other and begin to 
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secrete the matrix of carbohydrates, proteins, and DNA. Genetically, S. aureus forms a biofilm 
when the accessory gene regulator (agr) locus that encodes a quorum-sensing system is down 
regulated to allow for attachment. Additionally, the regulatory locus staphylococcal accessory 
regulator (sarA) is expressed due to its importance in the control of the intracellular adhesion 
(ica) operon9, which is vital for biofilm development. Products of the ica operon are responsible 
for the biosynthesis of polysaccharide intercellular adhesin (PIA), the main molecule used in 
intercellular adhesion in staphylococci.10  
 It is known that human hospital strains of S. aureus can produce a biofilm that enables 
their prolonged environmental presence and increased microbial resistance. Therefore, research 
has been conducted on ways to fight and eradicate biofilm-producing pathogens, by taking into 
account the unique features of biofilm when developing disinfectant protocols.11 These same 
advancements to cleaning procedures have not occurred in veterinary medicine because 
currently, little research exists on the potential of veterinary hospital strains of S. aureus to 
produce biofilms. Recent increases in veterinary surface contamination as well as the long-term 
survival of S. aureus in veterinary environments necessitate that this research be conducted.3 It is 
hypothesized that, because of epidemiological similarities between S. aureus strains isolated 
from a veterinary hospitals and human hospitals, veterinary strains will similarly be capable of 
producing biofilm. The results of this research will aid in the protection of both veterinary 
hospital staff and patients by ensuring that the control of zoonotic transmission takes into 
account all virulent characteristic of this potentially deadly pathogen.  
 In order to quantify the biofilm production capabilities of an isolate, the Crystal Violet 
(CV) assay is often preferred due to its simplicity, reliability, and quick throughput. This method 
allows for the in vitro cultivation and quantification of bacterial biofilms.12 The CV 
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nonspecifically stains all biomass, both living and dead, as well as the matrix composed of 
extracellular polymeric substances.13 This stain makes the assay useful to assess the overall 
biofilm response of an isolate.12 Through this method, an isolate can be classified as high, 
moderate, or non-biofilm producer. The objective of this study was to optimize the Crystal Violet 
phenotypic biofilm screening technique for S. aureus. In doing so, high, moderate, and non-
biofilm producing controls were validated for future assays for which clinical isolates can be 
statistically compared to controls and characterized as high, moderate, or non-producers. The 
information obtained about these clinical isolates of veterinary origin will help to better 
understand the potential role of biofilm production in the ecology and epidemiology of S. aureus 
in veterinary hospitals. This information can then be used to revise and enhance cleaning and 
disinfecting protocols to better ensure the safety of patients and hospital staff.  
PROCEDURES AND METHODS 
Control Strains 
 Two well characterized high biofilm producing S. aureus strains (Sa+), NE95 and 
NE1241, one well characterized moderate biofilm producing S. aureus strain, wild type JE2 
(WT), and one well characterized non-biofilm producing S. aureus strain (Sa-), NE1193, were 
obtained and used to optimize CV protocol.  
High Producers 
NE95 (agr-) is a high biofilm producing isolate. It has been found that the presence of this 
quorum-sensing accessory gene regulator (agr) locus is responsible for cell-to-cell 
communication. The presence of this locus inhibits the attachment and development of biofilm. 
By mutating this locus, NE95 is known to form more robust biofilms compared to wild type 
strains and thus, have improved biofilm development capabilities.14 
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NE1241 (nucA-) lacks a nucA gene that is known to control the expression of the enzyme 
Thermonuclease (nuc). It has been shown that suppression or removal of nuc enhances biofilm 
formation, promoting the high producing phenotype.15 There is therefore an inverse correlation 
between nuc activity and biofilm formation.16  
Moderate Producer 
JE2 (WT) is a wild-type strain of S. aureus known to produce a moderate amount of biofilm 
under proper conditions.10, 15 
Low Producer 
NE1193 (sarA-) lacks the accessory regulatory A (sarA) locus, which is involved in the 
regulation of extracellular and cell wall proteins in S. aureus.17 For this reason mutation	of	sarA	results	in	a	reduced	biofilm	formation	capacity	of	S.	aureus.18 
Crystal Violet Assay 
 The developed CV assay was adapted from the Microbial	 Infection	 and	 Immunity	Microbiology	Center	for	Microbial	Interface	Biology,	The	Ohio	State	University. Briefly, the 
isolates were first inoculated	 on	 Trypticase	 Soy	 Agar	 (TSA),	 a	 growth	 medium,	 and	incubated	overnight	 at	 37°C.	 	 Then,	 1	 colony	was	 added	 to	5mL	of	Trypticase	 Soy	Broth	(TSB)	and	grown	overnight	at	37	°C	in	shaker	at	200	rpm.	50	uL	of	overnight	culture	was	then	added	to	5	mL	of	TSB	and	an	overday	culture	was	grown	at	37°C	 for	2-3	hours	 in	a	shaker	at	200	rpm.		Using	a	spectrophotometer	blanked	with	TSB,	the	overday	incubation	was	stopped	when	the	OD600	was	between	0.5	and	0.7.	Each	well	of	a	96-well	tissue	culture	plate	 was	 then	 inoculated	 with	 200	 uL	 of	 overday	 culture	 at	 ~0.5	 OD600;	 6	wells/plate/isolate	for	3	repetitions.	The	plate	was	then	grown	statically	at	37°C	overnight.	After,	180	uL	of	each	well	of	the	96-well	plate	was	aspirated	and	the	plate	was	washed	in	
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large	beaker	of	water	for	5	rigorous	passes.	It	was	then	blotted	on	paper	towels	2-5	times.	Next,	200	uL	of	0.1%	aqueous	CV	was	added	to	each	well	and	the	plate	was	left	to	stand	on	the	bench	for	30	minutes.	180	uL	of	each	well	of	the	96-well	plate	was	aspirated	again	and	then	 the	 plate	 was	 washed	 in	 large	 beaker	 of	 water	 for	 5	 rigorous	 passes.	 It	 was	 then	blotted	 on	 paper	 towels	 2-5	 times.	 To	 elute	 the	 bound	 CV,	 200	 uL	 of	 95%	 ethanol	 was	added	to	each	well	and	the	plate	was	left	to	stand	on	the	bench	for	30	minutes.	Lastly,	the	lid	was	removed	and	the	plate	is	read	with	a	microplate	reader	at	540	nm.	This	CV	assay	was	 optimized	 for	 equipment	 in	 the	 Diagnostic	 and	 Research	 Laboratory	 on	 Infectious	Diseases	(DRLID),	The	Ohio	State	University.		
Data	Analysis 
 To analyze the results of the plate readings, a one-way ANOVA test is run with a 
Bonferroni post-hoc analysis. The one-way ANOVA test is	 used	 to	 determine	 if	 there	 are	significant	 differences	 between	 the	 means	 of	 plated	 isolates. The Bonferroni post- hoc 
analysis	allows	for	comparison	between	data	groups	within	the	plate.	The	CV	assay	control	strains	 are	 preforming	 optimally	 when	 there	 is	 significant	 difference	 between	 the	 high,	moderate,	and	non-producers.	
RESULTS AND DISCUSSION  
To ensure the CV technique performed sensitively, specifically, and reliably optimization 
of the quantity of overday culture growth, overnight incubation time, aspiration quantities, 
washing technique, and microplate reader absorbance wavelength were required.  
Overday Culture  
 The original CV assay required the use of a test tube direct read spectrophotometer, 
which read the turbidity of the overday culture directly from the incubated test tube. In the 
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current study, a spectrophotometer requiring 2 mL cuvette subsamples for each reading was 
used. It was found that on average, two subsample readings were taken before the desired 0.5 
OD is reached, increased the odds of running out of sample for plating. Therefore, the protocol 
was revised as follows: 90	uL	of	 overnight	 culture	 is	 added	 to	9	mL	of	TSB.	This	 revision	preserves	the	overnight:TSB	ratio	of	the	original	protocol,	50		uL	of	overnight	to	5	mL	of		overday	 or	 0.01%,	 and	 provides	 enough	 volume	 for	subsampling	 and	 plating.	 However,	 as	 seen	 in	 Table	 1,	 this	new	 volume	 of	 overday	 culture	 volume	 took	 an	 average	 of	4.919	hours,	 rather	 than	 the	expected	2	 to	3	hours,	 to	 reach	an	OD600	of	~0.5.		We	suspected	that	the	increased	volume	(5		mL	to	9	mL)	in	the	10	mL	test	tube	did	not	provide	the	culture	with	optimal	oxygen	for	an	exponential	 growth	 response.	 To	 resolve	 this	 issue,	 the	protocol	was	 further	modified	 125	mL	Erlenmeyer flasks were 
used in place of 10 mL test tubes. To these, 400 uL of overnight 
culture is added 40mL of TSB. This modification resulted in the 
return of the expected overday growth time of 2.722 hours on 
average as seen in Table 2. 	
Overnight Incubation Time 
 The overnight incubation time of the 96-well plate was increased from 18 to 24 hours due 
to a recommendation of the Microbial	 Infection	 and	 Immunity	 Microbiology	 Center	 for	Microbial	 Interface	 Biology,	 The	 Ohio	 State	 University. This additional incubation time is 
believed to allow for further maturation and improved adhesion of the biofilm to the plate. This 
Table	1:	Average	overday	
incubation	time		
90	uL	(culture):9	mL	(TSB)	
Run	 Date	
To	Reach	OD600	
(hrs)	
1	 10.12	 5.000	
2	 10.21	 4.925	
3	 10.29	 4.833	
		 		 4.919	
Table	2:	Average	overday	
incubation	time		
400	uL	(culture):	400	mL	(TSB)	
Run	 Date	
To	Reach	OD600	
(hrs)	
1	 3.2	 2.833	
2	 3.7	 3.000	
3	 4.12	 2.333	
		 		 2.722	
9	
Figure	1:	Post-wash	pooling	
increased adhesion makes the biofilm more durable to withstand the CV assay, particularly the 
washing steps.  
Aspiration  
 Originally, 180 uL was the suggested cell culture quantity to be aspirated from the wells. 
However, our observations are that removing this quantity leads to a disturbance of the S. aureus 
growth at the bottom of the well. One possible cause of this disturbance could be that there is an 
evaporation of media during incubation that leads 180 uL to be an overestimate of removable 
free cell culture. To avoid the removal or disturbance of intact biofilm, the protocol was 
modified to aspirate 150 uL before moving onto the wash step.  
Washing 
 The wash steps, which occur twice in the protocol, have the potential to introduce more 
variability into the results than any other step. Ideally, washing should remove all non-adherent 
cells while still preserving the integrity of any biofilm.12 During adaption of the CV assay, two 
components of the wash required significant modification: the washing technique and the 
number of washes. In the 
original protocol, the washing 
technique began after wells 
were aspirated. First, plates 
were inserted into a beaker of 
distilled water at a 90-degree 
angle. The plate was then 
vigorously passed back and 
forth five times. Immediately 
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Figure	2:	Bucket	vs.	Blot	Washing	Technique	
after, it was blotted on paper towels 2-5 times. This technique was difficult to perform efficiently 
as the plates remained wet inside and out and there was potential for splash of infectious 
material. It was also difficult to eliminate inconsistently washed wells and pooling of excess CV 
and water within wells. This was particularly noticeable in the wash after the crystal violet stain; 
as seen in Figure 1, many wells contained pools of 
purple tinted water around the perimeter of the bottom 
of each well even after the final wash step. This leftover 
material that was not properly removed by the wash, 
artificially elevated the CV absorbency reading of each 
well beyond the limit of the plate reader, which did not 
allow for differentiation between high, moderate, and 
non-biofilm producers. Inserting the plate into the 
bucket at a 45-degree angle was a modification made to 
fix these inconsistencies, but the data was still 
immeasurable. To further modify the assay, the bucket 
technique was completely eliminated. Instead, after 150 uL is aspirated from the wells, the plates 
are forcefully ‘blotted’ onto paper towels 3 times to remove remaining liquid while preserving 
the biofilm on the bottom of the wells. Next, 200 uL of double distilled water is pipetted into 
each well. Immediately after, 180 uL of the water is then pipetted out of the wells. The plates are 
forcefully ‘blotted’ again onto paper towels 3 times to remove remaining liquid. This wash is 
repeated once more.  Figure 2, compares a plate created using the bucket technique (top) vs. a 
plate created using the new blotting technique (bottom). This new washing technique eliminated 
leftover material such as excess CV, allowing for differentiation between high,  
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moderate, and non-biofilm producers. With this new 
technique averages for each control strain have been 
identified after 4 replications of 18-wells/control strain/plate 
and are seen in Table 3.  
 
Measurement of Results 
 The original CV assay required the optical density of each well containing solubilized  
 Crystal Violet stained cells be read with a microplate reader at 540 nm. However, a spectrum 
analysis of 4 plate replicates between 540 and 600nm on an increment of 10nm suggested that 
the max OD was recorded at 590nm. This was confirmed with an additional spectrum analysis 
between 580 and 600nm on an increment of 5nm.  The magnitude of absorbance is important 
because we are trying to detect small amounts of material. For this reason it is critical to measure 
at the most sensitive wavelength, or the wavelength of maximum absorbance, which for this 
assay is 590nm. Figure 3 shows an example of the two spectrum analyses used to determine an 
optimal absorbance of 590nm for each plate.   
 
Table	3:		Control	Strains		
Strain	
Average	Absorbance	
@	590nm	
NE1241	 0.68	
WT	JE2	 0.64	
NE1193	 0.47	
NE95	 0.79	
Figure	3:	Spectrum	analysis	540-600nm	and	580-600n	
Spectrum-A1
Spectrum-B1
Spectrum-C1
Spectrum-D1
Spectrum-E1
Wavelength (nm)
O
D
540 550 560 570 580 590 600
0.300
0.400
0.500
0.600
0.700
0.800
0.900
Spectrum-A1
Spectrum-B1
Spectrum-C1
Spectrum-D1
Spectrum-E1
Wavelength (nm)
O
D
584 586 588 590 592 594 596 598 600
0.400
0.450
0.500
0.550
0.600
0.650
0.700
0.750
0.800
0.850
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Control	Strains	 	 Although	NE1241 (nucA-) was intended to perform as a high	producing	strain,	 in	all	trials	 it’s	 absorbance	 readings	 were	 not	 statistically	 greater	 than	 WT	 JE2	 (P<	 0.05).		Fortunately,	NE95 (agr-) consistently preformed as a high producer (Graph 1). It is important 
that a high, moderate, and non-biofilm 
producing strain were identified and verified 
because the CV assay requires these controls 
to be plated and compared with clinical 
isolates to allow for clinical isolate 
characterization. NE95 was verified as a high 
biofilm producer, WT JE2 as a moderate 
biofilm producer, and NE1193 as a non-
biofilm producer.   
CONCLUSIONS 
 This study identified the most critical points of the CV assay that required optimization 
for future clinical applications.  Changing the quantity of overnight added to TSB as well as the 
glassware involved in the overday culture growth resolved the issues of subsampling and slow 
growth. Increasing overnight incubation time allowed for more mature and durable biofilm 
growth within the 96-well plates. Decreasing aspiration quantities better preserved any biofilm 
growth on the bottom of the well. Revising the washing technique to involve blotting and 
pipetting rather than a bucket more thoroughly removed excess cells, water, and CV stain. 
Preforming spectrum scans using a microplate reader confirmed a revision in the optimal 
absorbance wavelength in which plates should be read. All of these changes have lead to the 
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Graph	1:	Control	isolate	absorbance	@	590nm	
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optimization of the CV assay. In the future, this standardized Crystal Violet assay for quantifying 
biofilm mass can be implemented to screen the biofilm production capabilities of S. aureus 
isolates obtained from a veterinary teaching hospital during routine surveillance over a span of 
seven years. Through this method, using the defined control strains, the biofilm production of a 
clinical isolate can be classified as high, moderate, or non-producing. This data can be 
incorporate with previous epidemiological information associated with each isolate. The 
information obtained could help to better understand the potential role of biofilm production in 
the ecology and epidemiology of S. aureus in veterinary hospitals. This information can then be 
used to revise and enhance cleaning and disinfecting protocols to better ensure the safety of 
patients and hospital staff.  
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